Hims & Hers Health (HIMS-N)

It's fallen 15% in the past week after rallying 18% this year. They offer cheaper weight-loss drugs than peers, until last Friday, the FDA said it couldn't sell them anymore (Novo Nordisk's shortage is over).

It reports Monday. The market is skeptical that HIMS can still produce the cheaper version of the GLP-1 weight-loss drug, after a court ruling to stop producing this version. Shares plunged 25.79% today. Take profits.

HIMS has been picking up plenty of steam recently. It's results have continued to come in strong, it is up 225% year-to-date and it is not overly expensive at 34.5x forward earnings. HIMS is a telethealth platform that connects consumers and healthcare professionals. It has a wide product/service offering and growing subscription based model. Revenue growth has been very high (50%+), and it has been becoming increasingly profitable over recent quarters. The balance sheet also has no debt and it has been increasing cash flows nicely. It has a strong business model and fundamentals while growth is expected to continue to be high. We think it looks good and if profitability continue to ramp up the valuation could look more attractive. 
Unlock Premium - Try 5i Free  

Likes it. Is up 129% this year, but isn't expensive, considering all its growth.

It's a healthcare platform that lets users talk to doctors and buy generic treatments for various sensitive and embarrassing conditions like baldness and weight. Shares soared 30% when it reported Q4 last February, then kept rising. They reported strong growth, profits and guidance. They reported another beat in May, because they were offering more products, namely weight-loss drugs, including GLP-1 injections which are in high demand. But these aren't the patented drugs from Eli Lilly and Novo Nordisk, but copycats (legal) at a much lower price. Shares jumped on this May 20 news. Then in late June a media report stated that HIMS was getting this drug from a supplier that had previously unreported, ties to fraud and bankruptcy, and that users can get these drugs without a prescription, which opens HIMS to litigation risk. Shares fell back to $20, which is an attractive level to enter. He has mixed feelings. The company was good before GLP-1 and good overall.